Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 2/20 | 0.33 |
| ▸ | ACE | P12821 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18573595 | 0.83 | LMNA (0.55) | HSD17B10LMNACYP2C19RENACE | |
| SCHEMBL18576765 | 0.80 | HSD17B10 (0.36) | HSD17B10LMNACYP2C19PREPPOLB | |
| SCHEMBL2259135 | 0.75 | HSD17B10 (0.56) | HSD17B10LMNAPOLB | |
| SCHEMBL26167163 | 0.73 | LMNA (0.33) | HSD17B10LMNACYP2C19POLBDPP4 | |
| SCHEMBL5469910 | 0.73 | LMNA (0.46) | HSD17B10LMNACYP2C19PREPREN | |
| SCHEMBL20416167 | 0.70 | KMT2A (0.40) | POLBL3MBTL1 | |
| SCHEMBL4442776 | 0.69 | CA12 (0.38) | RENACE | |
| SCHEMBL20221686 | 0.68 | PREP (0.41) | HSD17B10LMNACYP2C19PREPREN | |
| SCHEMBL3085600 | 0.67 | LMNA (0.58) | HSD17B10LMNACYP2C19RENACE | |
| SCHEMBL31122771 | 0.67 | LMNA (0.58) | HSD17B10LMNACYP2C19RENACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2311798-A1 | 4-dedimethylamino tetracycline compounds | Paratek Pharmaceuticals, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |